PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
- Conditions
- Biological Availability
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT06137703
- Locations
- 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Biological: COMIRNATY intramuscular injection
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT06130410
- Locations
- 🇯🇵
Pfizer Local Country, Tokyo, Japan
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT06125522
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸UCHealth Harmony, Fort Collins, Colorado, United States
A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers
- Conditions
- Healthy
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06122194
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
- Conditions
- Healthy Participants
- Interventions
- Biological: mPnC candidateBiological: mPnC control
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT06116591
- Locations
- 🇫🇮
FVR, Kokkolan rokotetutkimusklinikka, Kokkola, Mellersta Österbotten, Finland
🇫🇮FVR, Tampereen rokotetutkimusklinikka, Tampere, Pirkanmaa, Finland
🇫🇮FVR, Oulun rokotetutkimusklinikka, Oulu, Pohjois-pohjanmaa, Finland
A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
- Conditions
- Pediatric Growth Hormone Deficiency
- Interventions
- Device: Sharps bin to collect used needles/injections
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT06113952
A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT06106009
- Locations
- 🇺🇸
Pfizer Clinical Research Unit - New Haven, New Haven, Connecticut, United States
A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT06105983
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
- Conditions
- Migraine
- Interventions
- Combination Product: Zavegepant 10 mgCombination Product: Placebo - Control 1Combination Product: Placebo - Control 2
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1280
- Registration Number
- NCT06103734
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 333
- Registration Number
- NCT06105632
- Locations
- 🇦🇷
Fundación CORI para la Investigación y Prevención del Cáncer, La Rioja, Argentina
🇦🇷COE (Centro Oncológico de Excelencia), San Juan, Argentina
🇦🇷Sanatorio Norte, Santiago del Estero, Argentina